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Retroviral mutagenesis has been used as a powerful tool to discover genes involved in oncogenesis through a technique called Common
Insertion Site (CIS) analysis where tumors are induced by proviral integrations and the genomic loci of the proviruses are identified. A
fundamental assumption made in this analysis is that multiple proviral insertions in close proximity occurring more frequently than would be
predicted randomly provides evidence that the genes near the integrations are involved in the formation of the tumors. We demonstrate here using
data derived from MLV integrations not put under selection for tumor induction that CIS analysis as currently defined is often not a sufficient
argument for a gene’s significance in tumorigenesis.
D 2005 Elsevier Inc. All rights reserved.Keywords: Insertion site; Gene; TumorigenesisFor nearly 100 years, it has been known that viruses can be
oncogenic (Ellerman and Bang, 1908; Rous, 1911). One of the
best studied of such viruses is the Murine Leukemia Virus
(MLV), which as its name implies, is responsible for increased
numbers of cancers in the blood lineages (Friend, 1957; Gross,
1957). Recently, this property has been used in combination
with high-throughput genomic approaches as a probe for genes
involved in oncogenesis (Johansson et al., 2004; Kim et al.,
2003; Lund et al., 2002; Mikkers et al., 2002; Shin et al., 2004;
Suzuki et al., 2002). The basic approach is to infect mice with a
wildtype virus that will propagate and, at a high rate, induce
cancers. These tumors are isolated and the proviral integrations
are mapped to genomic locations. Suzuki et al. (2002) were the
first to use this approach on a large scale and they generated a
model for defining what is known as a Common Insertion Site
(CIS). This model compares the mapped locations of the
proviruses in the isolated tumors to randomly generated
integrations from 100,000 Monte Carlo trials. This allowed0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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E-mail address: burgess@mail.nih.gov (S.M. Burgess).them to determine cutoffs for defining when two or more
integrations in close proximity were significant enough to
assume it didn’t happen by chance (and by extension was
involved in the tumorigenesis). From this analysis, they were
able to develop criteria for CIS significance. Basically the
cutoffs were within 30 kb for 2 integrations, 50 kb for 3
insertions or 100 kb for 4 or more integrations. Of particular
note is that the criteria predicted approximately 16 false
positives in the 2 insertion/30 kb cutoff (using 1200 integra-
tions). Other criteria involved direct human interpretation of
the data, but the fundamental model has been used several
times since the original publication (Johansson et al., 2004;
Kim et al., 2003; Lund et al., 2002; Mikkers et al., 2002; Shin
et al., 2004). Given the lack of knowledge about integration
sites biases for MLV, comparison to randomly generated sets of
integrations was a reasonable assumption.
Recently we mapped 903 MLV integrations in HeLa cells
(Wu et al., 2003). These integrations were not subject to any
form of selection, so it is assumed that this data set does not
have the selective bias of requiring oncogenesis used in CIS
analysis. Analysis of this data set demonstrated that MLV
showed a pattern of integration that was clearly not completely6) 292 – 295
www.e
Table 1
Comparison of the number of common insertion sites generated an unselected
set of retroviral integrations (Unselected MLV) when compared to those
generated in Suzuki et al as causative for tumorigenesis (CIS) and their random
integration model (Random)
Randoma Unselected MLVb CISc
2 integrations 16.3 59.8 95
3 integrations 0.3 4.0 21
4+ integrations 0.4 4.0 (0) 28 (17)
Particularly in the 2 integration category, there is an enrichment for CIS
occurrences in the unselected integrations when compared to random.
a Number taken from Suzuki et al. (web supplement) based on 100,000
Monte Carlo simulations.
b Based on data from Wu et al. Number is normalized to the Suzuki et al. data
by the formula: (n/903)1200, where n = the number of CIS based on criteria
from Suzuki et al. Number in parentheses is the number of CIS with greater
than 4 integrations.
c From Suzuki et al. Based on 1200 integrations. Number in parentheses is
the number of CIS with greater than 4 integrations.
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within T5 kb of the transcriptional start site (Refseq genes,
Nov. 2002, UCSC human genome Hg13), where in a randomly
generated set that frequency was approximately 4% (P <
0.0001). In terms of the null hypothesis for CIS analysis this is
problematic. The criteria CIS’s are based on a comparison to a
random set, but there is a clear bias in integration sites even
without selection, therefore the null hypothesis for CIS analysis
must now take this non-random behavior into account.
To establish how much of a problem the intrinsic biases of
MLV site selection to CIS analysis are, we remapped the MLV
integrations to the most current build of the human genome
(May 2004, UCSC human genome Hg17). We then applied the
original criteria for CIS analysis, ignoring any CIS determined
by human interpretation (i.e. integrations near a known
oncogene) and then normalized the data to the number of
integrations mapped by Suzuki et al. The data are summarized
in Table 1 (see supplemental data for precise coordinates for all
the CIS). The major feature of this analysis is the relatively
high incidence of CIS sites in the unselected MLV data,
particularly when the criterion is two integrations within 30 kb.Fig. 1. The frequency of retroviral integrations creating common insertion sites (CIS)
Wu et al., 25% of the integrations were shown to land T5 kb of the transcriptional star
features. The model allows 75% of the integrations to occur randomly and 25% to in
simulation was then tested with all genes as targets, or increasingly smaller numbers
Not until the genes are limited to 5% of all genes are CIS generated at a rate nearUsing this definition, nearly two thirds of the 2-integration
CIS’s (59.8 of 95) in Suzuki et al. can be explained by the null
hypothesis of natural retroviral site biases. When looking at 3
integration CIS’s nearly 20% (4 of 21) integrations can again
be explained by the null hypothesis. Once the integration
number in the CIS is over 4, an interesting division occurs.
After normalization in the unselected set of MLV integrations,
there were 4 CIS with 4 integrations and 0 CIS with more than
4 integrations. In Suzuki et al., there were 11 CIS with 4
integrations, 17 CIS with more than 4 integrations, and one CIS
having 55 integrations (Sox4). This would suggest that CIS
with 3 or 4 integrations would still need an additional level of
proof with more than a 20% chance of a false positive, while
integration frequencies above 4 would be extremely rare in the
null hypothesis of no selection.
One argument that has been used to demonstrate the efficacy
of CIS analysis is that many genes identified by the analysis
had already been demonstrated to have a role in oncogenesis
using other methods. We determined the closest gene for each
CIS in the unselected MLV data. We selected only the genes
that have at least one publication associated with them and
searched PubMed for the name of the gene in combination with
the word cancer. Of the 38 genes tested in this fashion, 14
(37%) of them could be demonstrated to be positively
associated with cancer using only this simple and far from
comprehensive criterion (see supplemental data). This small
exercise demonstrates that a pre-established role in cancer is
not sufficient support for the efficacy of the CIS technique. We
previously demonstrated that MLV integrations are biased
towards genes with higher expression levels (Wu et al., 2003)
and the integration mapping was done in the tumor derived
HeLa cells. Thus, it can be argued that MLV is biasing
integrations into locations that are transcriptionally more active
because the genes are related to cancer formation. Therefore, it
may be unclear if the integrations are causative for the tumor or
are targeted to that location because it is a tumor.
We developed a simple model to simulate the integration
biases we had established in our original paper. Instead of
simulating completely random integration, we limited 25%using various models of integration and repeated 1000 times for each model. In
t site, and 75% were considered equivalent to random based on various genomic
tegrate in a Poisson distribution T5 kb around the transcriptional start site. The
of genes available for integration (to imitate biases for level of gene expression).
that of our experimental data.
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human genome freeze) of the integrations to a Gaussian
distribution T5 kb around the transcriptional start site of
RefSeq genes. The remaining 75% of the integrations were
allowed to integrate randomly (Fig. 1). We then ran the
simulation 1000 times on the mouse genome (MM5) with 1200
integrations in each simulation to match the number of
integrations from Suzuki et al. This model was indistinguish-
able from random integration in terms of CIS frequency (Fig. 1
red and blue lines). MLV also has a bias towards more highly
expressed genes. As a way to simulate restricted integration
based on the level of gene expression in addition to the
preference for the 5V end of genes, we used the simple model of
considering genes to be either ‘‘on’’ or ‘‘off’’ and only allowed
the 25% category of integrations in genes to ones that were
‘‘on’’. We tested models that used 1/2, 1/5, 1/10, and 1/20 of the
total 18,366 RefSeq genes in the current mouse genome build
MM5 (Fig. 1). It was not until we limited the model to 1/20 of
the RefSeq genes that we were able to demonstrate CIS
frequencies similar to those seen in our data set. The average
number of CIS was approximately 55, with the highest seen
being 69 CIS. We examined our original integration data to
determine how many of the CIS in our unselected viral
integrations had at least one integration within T5 kb of the
transcription start site. Only 15 of the 68 CIS satisfied this
criterion. This was a strong indication that the 5V bias and gene
expression were not the only factors influencing integration
position.
There are two important ramifications that come from our
analyses. The first is that there appears to be additional factors
influencing MLV site selection beyond the previously described
affinity for the 5V ends of genes. Our modeling demonstrates
that such a bias is insufficient to explain the frequency of CIS in
our unselected integrations without an extreme limitation in the
number of genes available for retroviral integration (1/20 of all
genes). As only 15 of the 68 CIS in our data have even one
integration near the 5V end of a gene, there must be other aspects
of the chromatin influencing proviral integration. We do not
currently know what features of chromatin are influencing these
chromosomal integration hotspots. One possible way of
thinking about the observed bias towards the 5V ends of genes
is that the transcriptional start regions of genes have structural
properties (e.g., open chromatin) that are similar to other regions
of the chromatin that also have a propensity for retroviral
integration. Thus, the 25% of integrations that appear to be
biasing towards the 5V ends of genes are merely a subset of the
total global chromatin features that are considered preferential
for MLV integration. Second, the traditional definition of a
common insertion site being statistically significant for tumor-
igenesis can no longer be used and a new definition must take
into account the natural biases of whatever virus is being used.
The data from our unselected integrations generates CIS at a
frequency high enough to create problems with interpretation
based on the traditional definition. Nearly 2/3 of the CIS that
consist of 2 integrations within 30 kb could be accounted for by
the null hypothesis of no selection and 20% of the 3 or 4
integration CIS’s. Only when integration frequencies get above4 integrations in a CIS (from a data set of around 1200
integrations) can you definitively say that the CIS is highly
unlikely to occur by chance. It is quite likely, even probable that
the CIS of 4 and below are significant in tumorigenesis, but they
would require a much higher level of proof to their significance
than what is supplied by CIS analysis, as they could realistically
have occurred by chance.
In conclusion, CIS analysis is a very powerful tool for
identifying candidate genes involved in oncogenesis as well as
normal development, but the statistical analysis as it is
currently done does not take into account the natural
integration preferences of the retroviruses being used. These
biases have both the natural tendency to generate CIS’s as well
as to integrate into genes that are potentially relevant to cancer.
We propose a much more stringent criteria based on modeling
the unselected integration patterns of whatever retrovirus is
being used, and comparing that unselected model to the
observed integration frequencies in the tumors. For MLV
integrations, CIS of 5 or more integrations carry statistical
significance in a set of 1200, while below 5 integrations have
an increased possibility of occurring by chance. It is not clear
what the implications of this finding are for the potential
increased risk MLV based vectors have when used for gene
therapy. The indications are clear that there are genomic
regions that are preferentially targeted, but why or how those
regions are targeted is still unknown.
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Supplementary data associated with this article can be found
in the online version at doi:10.1016/j.virol.2005.08.047.
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